Literature DB >> 2873064

Phenol sulfotransferase in humans: properties, regulation, and function.

R M Weinshilboum.   

Abstract

Phenol sulfotransferase (PST) catalyzes the sulfate conjugation of phenolic and catechol drugs and neurotransmitters. All human tissues that have been studied in detail contain at least two forms of PST. One form is thermolabile (TL), catalyzes the sulfate conjugation of micromolar concentrations of dopamine and other phenolic monoamines, and is relatively resistant to inhibition by 2,6-dichloro-4-nitrophenol (DCNP). The other form is thermostable (TS), catalyzes the sulfate conjugation of micromolar concentrations of simple phenols such as p-nitrophenol, and is relatively sensitive to DCNP inhibition. These two forms of PST have been physically separated and partially purified from several human tissues, including an easily accessible tissue, the blood platelet. The biochemical properties of platelet PST are very similar to those of PST in human brain, liver, and small intestine. Individual differences in the basal activity of TS PST in the platelet are correlated with individual variations in the activity of this form of the enzyme in human cerebral cortex (r = .94, n = 15, P less than 0.001). In addition, both platelet TS and TL PST activities are correlated significantly with the extent of sulfate conjugation of orally administered drugs such as acetaminophen and methyldopa. These latter observations are compatible with the conclusions that platelet PST activity may reflect the activity of the enzyme at sites of drug metabolism, and that variation in PST activity is one factor responsible for individual differences in the sulfate conjugation of orally administered drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873064

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  14 in total

1.  Sulphation of o-desmethylnaproxen and related compounds by human cytosolic sulfotransferases.

Authors:  Charles N Falany; Peter Ström; Stellan Swedmark
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

2.  Stereoselective metabolism of RS-albuterol in humans.

Authors:  T Walle; E A Eaton; U K Walle; G R Pesola
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

3.  On the Molecular Basis Underlying the Metabolism of Tapentadol Through Sulfation.

Authors:  Ahsan F Bairam; Mohammed I Rasool; Katsuhisa Kurogi; Ming-Cheh Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

4.  Sulfation of 4-hydroxy toremifene: individual variability, isoform specificity, and contribution to toremifene pharmacogenomics.

Authors:  Vineetha Koroth Edavana; Ishwori B Dhakal; Xinfeng Yu; Suzanne Williams; Susan Kadlubar
Journal:  Drug Metab Dispos       Date:  2012-03-20       Impact factor: 3.922

Review 5.  Phenol sulfotransferase inheritance.

Authors:  R Weinshilboum
Journal:  Cell Mol Neurobiol       Date:  1988-03       Impact factor: 5.046

6.  Minoxidil sulphation in human liver and platelets. A study of interindividual variability.

Authors:  G M Pacifici; R Bigotti; G Marchi; L Giuliani
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity.

Authors:  U K Walle; G R Pesola; T Walle
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

8.  Genetic polymorphism for human platelet thermostable phenol sulfotransferase (TS PST) activity.

Authors:  R A Price; R S Spielman; A L Lucena; J A Van Loon; B L Maidak; R M Weinshilboum
Journal:  Genetics       Date:  1989-08       Impact factor: 4.562

9.  Substrate specificity of phenol sulfotransferase from primary cultures of bovine brain microvessel endothelium.

Authors:  A Baranczyk-Kuzma; K L Audus; R T Borchardt
Journal:  Neurochem Res       Date:  1989-07       Impact factor: 3.996

10.  Paracetamol elimination in Chinese and Indians in Singapore.

Authors:  H S Lee; T Y Ti; Y K Koh; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.